SRC & BCR-ABL inhibitor
Catalog No. S19-901B
| Catalog No. | Pack Size | Price (USD) | |
|---|---|---|---|
| S19-901B-05 | 5 mg | $60 | |
| S19-901B-25 | 25 mg | $120 | |
| S19-901B-BULK | BULK | Contact Us |
Overview:
Inhibits Src, Bcl/Abl and Lyn tyrosine kinases (IC50= 0.55, 3.0 and 8.5 nM respectively (1,2). Suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells (3).
References:
1. LJ Lombardo et al. J. Med. Chem. 2004 47:6658
2. S Nam et al. Cancer Res. 2005 65:9185
3. FM Johnson et al. Clin. Cancer Res. 2005 11:6924
CAS Registry Number:
302962-49-8
Molecular Formula:
C22H26ClN7O2S
Appearance:
White to off-white solid
Melting Point:
274-276oC
Molecular Weight:
488.0
Purity:
>98% (TLC); NMR (Conforms)
Solubilization:
May be dissolved in DMSO (200 mg/ml)
Aliases:
1. N-(2-chloro-6-methylphneyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide;
2. BMS-354825
Storage and Stability:
Store desiccated as supplied at -20oC for up to 1 year. Store solutions at -20oC for up to 2 months.
Molecular Structure:
|
Angiogenesis, Apoptosis/Autophagy, Cancer, Cytoplasmic Tyrosine Kinases, ERK/MAPK Pathway, Inflammation, Invasion/Metastasis, JAK/STAT Pathway
STAY CONNECTED
Fax: 1-604-232-4601
Friedman R et al., The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib BMC Cancer May 2020 10.1186/s12885-020-06782-9
Toll Free: 1-866-954-6273
info@signalchem.com